Natco Pharma Reports Strong Q2 FY26 Financials, ₹1,463 Cr Revenue & Strategic Investments
Natco Pharma announced strong Q2 FY26 results with ₹1,463 crore revenue and ₹517.9 crore PAT. The company highlighted robust product pipelines and strategic investments in cell & gene therapy. An earnings call is scheduled for November 14, 2025.
The announcement includes comprehensive quarterly financial results, details on key product pipelines, and substantial strategic investments in NCE and cell & gene therapy, all of which have a high potential to influence investor perception and future company performance.
The company reported strong financial performance with increased revenue and profit, along with significant strategic investments in advanced therapies and a robust product pipeline, indicating positive future prospects.
Natco Pharma Limited announced its Q2 FY26 Earnings Presentation for the quarter and half year ended September 30, 2025. Key consolidated financial highlights for Q2 FY26 include: * Total Revenue stood at ₹14,630 Mn (₹1,463 crore). * Pharma Export Formulations revenue was ₹11,470 Mn (₹1,147 crore). * Domestic Formulations Revenue reached ₹1,054 Mn (₹105.4 crore). * Earnings Before Interest Tax Depreciation and Amortization (EBITDA) was ₹6,792 Mn (₹679.2 crore), with an EBITDA Margin of 46.4%. * Profit before tax (PBT) for the quarter was ₹6,137 Mn (₹613.7 crore). * Profit after tax (PAT) for Q2 FY26 was ₹5,179 Mn (₹517.9 crore), with a PAT Margin of 35.4%. * Earnings per share (EPS) for Q2 FY26 was ₹28.94. * Net cash as of September 30, 2025, stood at ₹39,030 Mn (₹3,903 crore). The company also highlighted its key product pipeline in the USA, including numerous approved and pipeline Para IV products, with over 20 FTFs (including Sole and Shared) for molecules like Carfilzomib, Ibrutinib, Olaparib, and Semaglutide. Furthermore, Natco Pharma is making significant NCE | Cell & Gene Therapy Investments, including: * US$ 8 million in eGenesis, a biotechnology company focused on xenotransplantation. * Progress in NRC-2694, an orally administered small-molecule tyrosine kinase inhibitor for Head and Neck cancer, with a Phase 2 clinical trial approved by US FDA and patient recruitment underway. * US$ 2 million in Cellogen Therapeutics, focused on advanced cellular engineering and gene-therapy based approaches for leukemia, lymphoma, beta-thalassemia, and sickle cell disease. * US$ 1 million in Eyestem, a cell therapy company developing treatment for dry Age-Related Macular Degeneration (AMD). * US$ 1 million in Stero Therapeutics, focusing on novel therapy for metabolic diseases like Cushing's syndrome. An Earnings Call to discuss the operational and financial performance is scheduled for November 14, 2025, at 4 PM IST.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.